摘要
目的探讨吉西他滨联合顺铂治疗晚期非小细胞肺癌(NSCLC)的疗效。方法选取2013年3月~2015年3月于我院进行治疗的NSCLC患者140例,随机均分为观察组和对照组各70例。对照组患者静脉注射吉西他滨(1 000 mg/m^2,第1 d、8 d)。观察组患者静脉注射吉西他滨(1 000mg/m^2,第1 d、8 d)和顺铂(40 mg/m^2,第1 d、8 d)。每21 d为一个疗程,共持续4个疗程。比较两组的临床疗效与不良反应发生情况。结果经研究比较,观察组总有效率优于对照组(P<0.05);不良反应发生率低于对照组(P<0.05)。结论吉西他滨联合顺铂治疗晚期非小细胞肺癌疗效确切,副作用小,患者耐受性好。
Objective To investigate the effect of the combination of gemcitabine and cisplatin on non-small cell lung cancer（NSCLC）. Methods140 cases with NSCLC from March 2013 to March 2015 were divided into control group and experimental group randomly, the control group was given gemcitabine（1 000 mg/m-2 on the first and eighth day） and the observation group was given gemcitabine（1 000 mg/m-2 and cisplatin 40 mg/m-2 on the first and eighth day）, of 21 day cycle, treatment of four courses. The efficacy and adverse reaction were compared between the two groups. Results Compared with the control group, the total effective rate of the observation group was better than that of the control group（P〈0.05）, and the incidence of adverse reaction was lower than that of the control group（P〈0.05）. ConclusionGemcitabine combined with cisplatin in the treatment of advanced non-small cell lung cancer is effective, with little side effect and good tolerance.
出处
《中国继续医学教育》
2016年第15期160-161,共2页
China Continuing Medical Education
基金
洛阳市科技计划医疗卫生项目(1401085A-6)
关键词
吉西他滨
顺铂
非小细胞肺癌
Gemcitabine
Cisplatin
Non-small cell lung cancer
